178 results on '"Panichella, Giorgia"'
Search Results
2. Sex differences in transthyretin cardiac amyloidosis
3. Wild-Type ATTR Amyloidosis
4. Hereditary Transthyretin Amyloidosis
5. Valvular heart disease in patients with cardiac amyloidosis
6. Echocardiography-Derived Forward Left Ventricular Output Improves Risk Prediction in Systolic Heart Failure
7. Pathophysiology of Cardiac Amyloidosis
8. Safety and efficacy of levosimendan in patients with cardiac amyloidosis
9. The Fondazione Toscana Gabriele Monasterio app: a digital health system to improve wellbeing of inpatients with heart or lung disease
10. Screening the health status of people working in a university
11. Left ventricular outflow tract velocity-time integral improves outcome prediction in patients with secondary mitral regurgitation
12. Abstract 15619: Prevalence of Transthyretin Cardiac Amyloidosis in Elderly Subjects From the General Population: The Catch Study
13. Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
14. Amyloid seeding as a disease mechanism and treatment target in transthyretin cardiac amyloidosis
15. RNA-targeting and gene editing therapies for transthyretin amyloidosis
16. Insulin‐like growth factor binding protein‐7 in heart failure: The challenge of moving from risk prediction to a biomarker‐guided management
17. Metabolomics to predict heart failure development: A new frontier?
18. The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction
19. Subclinical cardiac damage in cancer patients before chemotherapy
20. Pirfenidone as a novel cardiac protective treatment
21. Cardiac protection by pirfenidone after myocardial infarction: a bioinformatic analysis
22. Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review
23. High-sensitivity troponins for outcome prediction in the general population: a systematic review and meta-analysis
24. Bridging Atrial and Ventricular Failure Through Biomarkers.
25. Heart failure with preserved ejection fraction risk after aortic coarctation surgery: The hidden threat.
26. Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up.
27. Dissecting the heart failure phenotype through phenomics
28. Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis
29. Shared and unique characteristics of metabolic syndrome in psychotic disorders: a review
30. CRISPR-Cas9 for the Treatment of Transthyretin Cardiac Amyloidosis
31. Echocardiographic predictors of outcomes in hypertrophic cardiomyopathy
32. Sex differences in transthyretin cardiac amyloidosis
33. Echocardiographic findings in subjects with an amyloidogenic apolipoprotein A1 pathogenic variant
34. Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis
35. Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction
36. Role of Imaging in Cardiomyopathies
37. 679 PROGNOSTIC IMPACT OF ECHOCARDIOGRAPHIC DERIVED PRECAPILLARY WEDGE PRESSURE AND PULMONARY VASCULAR RESISTANCES IN PATIENTS WITH HEART FAILURE
38. 1107 PLASMA CIRCULATING TRANSTHYRETIN FORMS IN PATIENTS WITH WILD TYPE TRANSTHYRETIN CARDIAC AMYLOIDOSIS
39. 737 CLINICAL AND PROGNOSTIC SIGNIFICANCE OF LEFT VENTRICULAR OUTFLOW TRACT VELOCITY TIME INTEGRAL (LVOT-VTI) IN PATIENTS WITH CHRONIC HEART FAILURE
40. 276 CIRCULATING FORMS OF PLASMA TRANSTHYRETIN IN PATIENTS WITH WILD-TYPE TRANSTHYRETIN AMYLOIDOSIS AND EFFECTS OF TREATMENT WITH TAFAMIDIS
41. 790 LEFT VENTRICULAR OUTFLOW TRACT VELOCITY TIME INTEGRAL OUTPERFORMS LEFT VENTRICULAR EJECTION FRACTION IN HEART FAILURE PATIENTS WITH SIGNIFICANT MITRAL REGURGITATION
42. Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis
43. Value of the HFA‐PEFF andH 2 FPEFscores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis
44. Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers
45. The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism
46. The Potential Anti-remodeling Effect of Paroxetine After Myocardial Infarction May Be Blunted by Beta-Blockers
47. Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers
48. Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
49. Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
50. Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.